CD8A and neoplasm: Systemically, immune signature of more favorable responses to ICI immunotherapy has been observed in patients, who at baseline had a diverse TCR repertoire (173), a higher number of CD8+ effector T cells in the periphery and at the tumor margin (174, 175), and a lower level of MDSC (176–178), and had higher levels of TCR repertoire (173, 179), increased levels of CD127low PD-1low CD4 T cells (180), and peripheral expansion of CD8+ T cells (181–183) at post-treatment.